HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Articles by Lorenzi, M. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Articles by Lorenzi, M. Social Bookmarking                What's this?

Early Complement Activation and Decreased Levels of Glycosylphosphatidylinositol-Anchored Complement Inhibitors in Human and Experimental Diabetic Retinopathy

From the Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts

Diabetic retinal microangiopathy is characterized by increased permeability, leukostasis, microthrombosis, and apoptosis of capillary cells, all of which could be caused or compounded by activation of complement. In this study, we observed deposition of C5b-9, the terminal product of complement activation, in the wall of retinal vessels of human eye donors with 9 ± 3 years of type 2 diabetes, but not in the vessels of age-matched nondiabetic donors. C5b-9 often colocalized with von Willebrand factor in luminal endothelium. C1q and C4, the complement components unique to the classical pathway, were not detected in the diabetic retinas, suggesting that C5b-9 was generated via the alternative pathway, the spontaneous activation of which is regulated by complement inhibitors. The diabetic donors showed a prominent reduction in the retinal levels of CD55 and CD59, the two complement inhibitors linked to the plasma membrane by glycosylphosphatidylinositol anchors, but not in the levels of transmembrane CD46. Similar complement activation in retinal vessels and selective reduction in the levels of retinal CD55 and CD59 were observed in rats with a 10-week duration of streptozotocin-induced diabetes. Thus, diabetes causes defective regulation of complement inhibitors and complement activation that precede most other manifestations of diabetic retinal microangiopathy. These are novel clues for probing how diabetes affects and damages vascular cells.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. Simo, M. Higuera, M. Garcia-Ramirez, F. Canals, J. Garcia-Arumi, and C. Hernandez Elevation of Apolipoprotein A-I and Apolipoprotein H Levels in the Vitreous Fluid and Overexpression in the Retina of Diabetic Patients Arch Ophthalmol, August 1, 2008; 126(8): 1076 - 1081. [Abstract] [Full Text] [PDF]

				W. Sun, P. J. Oates, J. B. Coutcher, C. Gerhardinger, and M. Lorenzi A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes, October 1, 2006; 55(10): 2757 - 2762. [Abstract] [Full Text] [PDF]

				D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al. Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease Diabetes, September 1, 2006; 55(9): 2401 - 2411. [Abstract] [Full Text] [PDF]

				S. P. Berger, A. Roos, and M. R. Daha Complement and the kidney: What the nephrologist needs to know in 2006? Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2613 - 2619. [Full Text] [PDF]

				K. Wenzel, J. Zabojszcza, M. Carl, S. Taubert, A. Lass, C. L. Harris, M. Ho, H. Schulz, O. Hummel, N. Hubner, et al. Increased Susceptibility to Complement Attack due to Down-Regulation of Decay-Accelerating Factor/CD55 in Dysferlin-Deficient Muscular Dystrophy J. Immunol., November 1, 2005; 175(9): 6219 - 6225. [Abstract] [Full Text] [PDF]

				C. Gerhardinger, M. B. Costa, M. C. Coulombe, I. Toth, T. Hoehn, and P. Grosu Expression of Acute-Phase Response Proteins in Retinal Muller Cells in Diabetes Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 349 - 357. [Abstract] [Full Text] [PDF]

				L. Zheng, C. Szabo, and T. S. Kern Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor-{kappa}B Diabetes, November 1, 2004; 53(11): 2960 - 2967. [Abstract] [Full Text] [PDF]

				X. Qin, A. Goldfine, N. Krumrei, L. Grubissich, J. Acosta, M. Chorev, A. P. Hays, and J. A. Halperin Glycation Inactivation of the Complement Regulatory Protein CD59: A Possible Role in the Pathogenesis of the Vascular Complications of Human Diabetes Diabetes, October 1, 2004; 53(10): 2653 - 2661. [Abstract] [Full Text] [PDF]

				Z. Dagher, Y. S. Park, V. Asnaghi, T. Hoehn, C. Gerhardinger, and M. Lorenzi Studies of Rat and Human Retinas Predict a Role for the Polyol Pathway in Human Diabetic Retinopathy Diabetes, September 1, 2004; 53(9): 2404 - 2411. [Abstract] [Full Text] [PDF]